PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors - Marker Therapeutics ( NASDAQ:MRKR )
HOUSTON, Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( NASDAQ:MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the ...
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
HOUSTON, Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the ...
Syndax Pharmaceuticals ( SNDX ) Reports Q3 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +5.41% and -5.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Syndax Announces Participation in November Investor Conferences - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( NASDAQ:SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Analysts Estimate Qiagen ( QGEN ) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Syndax Stock Down Today? - Syndax Pharmaceuticals ( NASDAQ:SNDX )
Shares of Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration. SNDX shares are retreating from recent levels. Track the action here.
Syndax Announces FDA Approval of Revuforj® ( revumenib ) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Syndax Pharmaceuticals ( NASDAQ:SNDX )
- First and only therapy FDA approved in both R/R acute myeloid leukemia ( AML ) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - - Second approved indication for Revuforj in less than one year further solidifies Syndax's leadership in menin inhibition -
Syndax Announces FDA Approval of Revuforj® ( revumenib ) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
- First and only therapy FDA approved in both R/R acute myeloid leukemia ( AML ) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation ...
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
NEW YORK, Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common ...
Syndax's Revuforj® ( revumenib ) Included in NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines® ) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® ( NCCN® ) Clinical Practice Guidelines in Oncology ( NCCN Guidelines® ) ...
Syndax's Revuforj® ( revumenib ) Included in NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines® ) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® ( NCCN® ) Clinical Practice Guidelines in Oncology ( NCCN ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
NEW YORK, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common ...
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth - Syndax Pharmaceuticals ( NASDAQ:SNDX ) , Kura Oncology ( NASDAQ:KURA )
Q2 loss narrowed to $0.83 per share vs. $1.00 expected; sales hit $37.96 million vs. $26.78 million consensus. Revuforj revenue jumped 43% sequentially to $28.6 million, marking strong commercial momentum. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Entergy ( NYSE:ETR ) , AptarGroup ( NYSE:ATR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Brent Bracelin initiated coverage on HubSpot, Inc.
Wall Street Analysts Believe Syndax ( SNDX ) Could Rally 112.8%: Here's is How to Trade
The mean of analysts' price targets for Syndax (SNDX) points to an 112.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
A posts fiscal Q3 earnings and revenue beats, with double-digit sales growth and upbeat guidance lifting shares.
Incyte ( INCY ) Up 9.4% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syndax Announces Participation in September Investor Conferences
NEW YORK, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will ...
Does Syndax ( SNDX ) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Syndax ( SNDX ) Q2 Revenue Jumps 986%
Syndax Pharmaceuticals ( NASDAQ:SNDX ) , a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025. The most notable news was its substantial GAAP revenue growth, driven primarily by commercial traction for its newly launched ...
Syndax Pharmaceuticals ( SNDX ) Reports Q2 Loss, Beats Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Syndax ( SNDX ) Rating Upgrade to Buy
Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Earnings Preview: Jazz Pharmaceuticals ( JAZZ ) Q2 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 237.83% Upside in Syndax ( SNDX ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, ...
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
- Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients ...
Syndax Presents New Revuforj® ( revumenib ) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
- 26% ( 20/77 ) CR+CRh rate and 48% ( 37/77 ) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population ...
Syndax Announces Participation in June Investor Conferences - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
Syndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, ...
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday - Amer Sports ( NYSE:AS ) , Agilysys ( NASDAQ:AGYS )
U.S. stocks were lower, with the Nasdaq Composite falling more than 50 points on Tuesday. Shares of Agilysys, Inc. AGYS rose sharply during Tuesday's session following better-than-expected fourth-quarter results.
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® ( revumenib ) and Niktimvo™ ( axatilimab-csfr )
- Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and ...
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® ( revumenib ) and Niktimvo™ ( axatilimab-csfr ) - Syndax Pharmaceuticals ( NASDAQ:SNDX )
- Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r - - Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with ...
Wall Street Analysts See a 219.98% Upside in Syndax ( SNDX ) : Can the Stock Really Move This High?
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Syndax Pharmaceuticals ( SNDX ) Reports Q1 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
NEW YORK, May 02, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to ...
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
CAMBRIDGE, Mass., May 01, 2025 ( GLOBE NEWSWIRE ) -- Foghorn® Therapeutics Inc. ( Nasdaq: FHTX ) , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., ...
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - AstraZeneca ( NASDAQ:AZN ) , BP ( NYSE:BP )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday. Shares of NXP Semiconductors N.V. NXPI fell sharply in today's pre-market trading after the company reported first-quarter financial results and issued second-quarter EPS guidance with its ...
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Algoma Steel Group ( NASDAQ:ASTL ) , AGM Gr Hldgs ( NASDAQ:AGMH )
Shares of Leggett & Platt, Incorporated LEG rose sharply in pre-market trading after the company reported better-than-expected first-quarter EPS results and raised its FY25 EPS guidance. Leggett & Platt reported quarterly earnings of 24 cents per share which beat the analyst consensus estimate of ...
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, April 28, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, ...
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
